Role of Novel RADA16 Hydrogel in Endoscopic Skull Base Surgery
NCT: NCT05898074 · RECRUITING
Brief Summary
The purpose of this study is to specifically evaluate the effectiveness of PuraGel, a RADA16 polypeptide hydrogel, in expediting post-operative healing and re-mucosalization of the nasoseptal flap harvest site during endoscopic skull base surgery and the impact on patient and sinonasal morbidity.
Frequently Asked Questions
What is Role of Novel RADA16 Hydrogel in Endoscopic Skull Base Surgery?
Role of Novel RADA16 Hydrogel in Endoscopic Skull Base Surgery is a clinical trial registered under NCT05898074. Current status: RECRUITING.
What is the status of NCT05898074?
The current status of NCT05898074 (Role of Novel RADA16 Hydrogel in Endoscopic Skull Base Surgery) is: RECRUITING.
When did Role of Novel RADA16 Hydrogel in Endoscopic Skull Base Surgery start?
Role of Novel RADA16 Hydrogel in Endoscopic Skull Base Surgery started on 2023-10-09.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.